Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patients

被引：0
|
作者：
Huguet, J. M. [1 ]
Iborra, M. [2 ]
Marti, L. [3 ]
Bosca-Watts, M. M. [4 ]
Ramirez, J. J. [5 ]
Ruiz, L. [1 ]
Sanchis, L. [6 ]
Garrido, A. [2 ]
Alemany, G. [3 ]
Suria, C. [4 ]
Paredes, J. M. [7 ]
机构：
[1] Hosp Gen Univ Valencia, Gastroenterol, Valencia, Spain
[2] Hosp Univ & Politecn Fe Valencia, Gastroenterol, Valencia, Spain
[3] Hosp Francesc Borja Gandia, Gastroenterol, Valencia, Spain
[4] Hosp Clin Univ Valencia, Gastroenterol, Valencia, Spain
[5] Hosp Lluis Alcanyis Xativa, Gastroenterol, Valencia, Spain
[6] Hosp Sagunto, Gastroenterol, Valencia, Spain
[7] Hosp Univ Dr Peset Valencia, Gastroenterol, Valencia, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P657
引用
收藏
页码：I1242 / I1242
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of subcutaneous infliximab in Crohn's disease patients with immunogenic failure of intravenous infliximab
    Husman, J.
    Cerna, K.
    Matthes, K.
    Gilger, M.
    Arsova, M.
    Schmidt, A.
    Winzer, N.
    Brosch, A. M.
    Hampe, J.
    Zeissig, S.
    Lukas, M.
    Schmelz, R.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1883 - I1884
  • [22] CLINICAL EFFICACY AND DURABILITY OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER SWITCHING FROM INTRAVENOUS INFLIXIMAB: A REAL-WORLD MULTICENTER PROSPECTIVE COHORT STUDY IN KOREA
    Kim, Kyuwon
    Hong, Sung Noh
    Kang, Sang-Bum
    Lee, Kang-Moon
    Koo, Ja Seol
    Jung, Yunho
    Lee, Beom Jae
    Yoon, Hyuk
    Kim, Hyung Wook
    Lim, Yun Jeong
    Lee, Hyun Seok
    Lee, Yoo Jin
    Lee, Jun
    Lee, Chang Kyun
    Moon, Jung Min
    Shin, Seung Yong
    Seo, Jeongkuk
    Choi, Chang Hwan
    GASTROENTEROLOGY, 2024, 166 (05) : S1136 - S1136
  • [23] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [24] Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Chetwood, John David
    Tran, Yvonne
    Subramanian, Sreedhar
    Smith, Philip J.
    Iborra, Marisa
    Buisson, Anthony
    Paramsothy, Sudarshan
    Leong, Rupert W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (09): : 1440 - 1449
  • [25] SUBCUTANEOUS INFLIXIMAB IN CROHN'S DISEASE PATIENTS WITH IMMUNOGENIC FAILURE OF INTRAVENOUS INFLIXIMAB: A RETROSPECTIVE TWO-CENTER STUDY
    Husman, Julia
    Cerna, Karin
    Matthes, Katja
    Arsova, Maia
    Schmidt, Alexandra
    Gilger, Maximilian
    Winzer, Nadia
    Brosch, Anna Magdalena
    Hampe, Jochen
    Zeissig, Sebastian
    Lukas, Milan
    Schmelz, Renate
    GASTROENTEROLOGY, 2024, 166 (05) : S1139 - S1139
  • [26] Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry
    Iborra, Marisa
    Caballol, Berta
    Garrido, Alejandro
    Huguet, Jose Maria
    Mesonero, Francisco
    Ponferrada, Angel
    Garcia, Lara Arias
    Watts, Marta Maia Bosca
    Prada, Samuel J. Fernandez
    Mas, Eduard Brunet
    Casbas, Ana Gutierrez
    Cerrillo, Elena
    Ordas, Ingrid
    Ruiz, Lucia
    de la Filia, Irene Garcia
    Ortiz, Jaime Escobar
    Sicilia, Beatriz
    Ricart, Elena
    Domenech, Eugeni
    Nos, Pilar
    JOURNAL OF CROHNS & COLITIS, 2024, 19 (01):
  • [27] Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
    Little, Robert D.
    Ward, Mark G.
    Sparrow, Miles P.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2430 - 2431
  • [28] Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
    Todeschini, A.
    Geccherle, A.
    Signoretto, P.
    Fasoli, E.
    Variola, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 551 - 552
  • [29] Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
    Mathieu, N.
    Riviere, P.
    Heluwaert, F.
    Hebuterne, X.
    Chupin, A.
    Bouguen, G.
    Vuitton, L.
    Allez, M.
    Montuclard, C.
    Nachury, M.
    Nancey, S.
    Amelie, B.
    Gilletta, C.
    Abitbol, V.
    Altwegg, R.
    De Maissin, A.
    Plastaras, L.
    Soune, P. Ah
    Boureille, A.
    Bouhnik, Y.
    Seksik, P.
    Chanteloup, E.
    Marion, S.
    Uzzan, M.
    Andrau, P.
    Rouillon, C.
    Arondel, Y.
    Biroulet, L. Peyrin
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 533 - 534
  • [30] PERSISTENCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCHING FROM INTRAVENOUS IN A FRENCH NATIONAL COHORT OF IBD PATIENTS IN REMISSION
    Mathieu, Nicolas
    Riviere, Pauline
    Heluwaert, Frederic
    Hebuterne, Xavier
    Chupin, Antoine
    Guillaume, Bouguen
    Vuitton, Lucine
    Allez, Matthieu
    Montuclard, Celine
    Nachury, Maria
    Nancey, Stephane
    Biron, Amelie
    Giletta, Cyrielle
    Abitbol, Vered
    Altwegg, Romain
    De Maissin, Astrid
    Plastaras, Laurianne
    Soune, Philippe Ah
    Bourreille, Arnaud
    Bouhnik, Yoram
    Seksik, Philippe
    Chanteloup, Elise
    Simon, Marion
    Uzzan, Mathieu
    Andrau, Pierre
    Rouillon, Clea
    Arondel, Yves
    Peyrin-Biroulet, Laurent
    Laharie, David
    GASTROENTEROLOGY, 2023, 164 (06) : S1118 - S1118
12345